期刊文献+

扶正化瘀解毒法治疗恶性肿瘤96例临床观察 被引量:5

Clinical observation of 96 cases of treatment of malignant tumor using Fuzheng Huayu Jiedu method
在线阅读 下载PDF
导出
摘要 目的:观察扶正化瘀解毒法对晚期恶性肿瘤患者体质、疼痛、血液指标的改善情况。方法:对96例晚期恶性肿瘤患者属正气亏虚,瘀毒内结证型者口服扶正化瘀解毒汤,并观察治疗前后患者的中医症候积分、生活质量评分、疼痛评分及血常规的变化情况。结果:治疗前中医症候积分由20.4±2.5下降至19.6±1.7,有统计学意义。治疗后25%的患者疼痛完全解除,52.8%的患者疼痛减轻,总有效率为68.9%;80%的患者卡氏评分有所上升,治疗前后白细胞由3.57±0.79×109/L上升至4.59±0.87×109/L,血小板由123±47×109/L上升至146±49×109/L,P<0.01,差异有统计学意义。结论:扶正化瘀解毒汤用于晚期恶性肿瘤患者的姑息治疗,有减轻疼痛,改善患者恶病质体质,提高患者身体状况的作用,且无肝肾毒性等不良作用,可用于晚期恶性肿瘤的治疗。 Objective:To observe the effect on body constitution,pain and blood index in advanced malignant tumor using Fu zheng HuaYu JieDu method.Method:Fuzheng Huayu Jiedu decoction was administered to 96 patients with advanced malignant tumor of Zheng Qi Kui Xu and Yu Du Nei Jie symptoms.And the scores of TCM symptoms,quality of life,pain and blood routine examination were investigated before and after treatment.Result:The scores of TCM symptoms were decreased from 20.4±2.5 to 19.6±1.7 which had statistical significance.Pain was completely removed in 25% patients,and was relieved in 52.8% patients with the total effective rate of 68.9%;KPS of 80% patients was increased.After treatment,the white blood count was increased from 3.57±0.79×109﹒L-1 to 4.59±0.87×109﹒L-1,and platelet was increased from123±47×109﹒L-1 to 146±49×109﹒L-1(P < 0.01).The difference was statistically significant.Conclusion:The Fuzheng Huayu Jiedu method can relieve pain,improve body constitution,improve the status of the body function in advanced malignant tumor patients.No toxicity and adverse effect on the liver and kidney are found.The results show that the method can be used for the treatment of late malignant tumor.
出处 《中药与临床》 2012年第5期22-24,共3页 Pharmacy and Clinics of Chinese Materia Medica
关键词 扶正化瘀解毒法 恶性肿瘤 晚期肿瘤 Fu zheng HuaYu JieDu method malignant tumor advanced stage tumor
  • 相关文献

参考文献9

二级参考文献17

  • 1管洪在,杨宗军,杨忠思,卢伟.恶性肿瘤患者血浆血栓调节蛋白、蛋白C抗原及D-二聚体含量的测定及其临床意义[J].中国实验诊断学,2005,9(4):521-523. 被引量:7
  • 2徐振晔,郑展.中医药分阶段防治恶性肿瘤术后复发转移优化方案探讨[J].中西医结合学报,2007,5(1):5-10. 被引量:49
  • 3Lee AY, Levine MN. Venous thromboembolism and cancer: risk sand outcomes [J]. Circulation, 2003, 107(23 Suppl 1):117.
  • 4Cheang PP, Fryer J, Ayoub O, et al. Spontaneous bilateral internal jugular vein thrombosis: a sign of metastasis [J]. J Laryngol Otol, 2004, 118(7):570.
  • 5Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients [J]. Cancer, 2007, 110(10):2339.
  • 6Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis[J]. Blood, 2008, 111(10):4902.
  • 7Thomas GM, Panicot-Dubois L, Lacroix R, et al. Cancer cell-deri ved microparticles bearing P-selectin glycoprotein ligand-1 accelerate thrombus formation in vivo [J]. Exp Med, 2009, 206(9):1913.
  • 8Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis[J]. Vasc Surg, 2003, 38(5): 1075.
  • 9Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 +2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study[J]. Clin Oncol, 2009, 27(25):4124.
  • 10Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer [J]. Thromb Res, 2001, 102(6): V215.

共引文献38

同被引文献65

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部